Filing Details

Accession Number:
0001415889-25-005325
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-24 17:52:59
Reporting Period:
2025-02-24
Filing Date:
2025-02-24
Accepted Time:
2025-02-24 17:52:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1539029 Clearside Biomedical Inc. CLSD Pharmaceutical Preparations (2834) 452437375
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1592380 Clay Thorp C/O Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta GA 30005
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-02-24 15,000 $0.92 176,141 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities.